Skip to main content

Table 1 Sensitivity of four human NSCLC cell lines to the anti-proliferative effect of erlotinib in vitro

From: Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET

Cell line Type of EGFR mutation IC 50 of erlotinib [μM] Erlotinib sensitive
QG56 None (wtEGFR) 8.9 ± 0.5*** No
HCC827 Activating (delE746-A750) 0.004 ± 0.0009 Yes
NCI-H3255 Activating (L858R point mutation) 0.041 ± 0.007 Yes
NCI-H1975 Double mutation (L858R + T790M point mutations) 4.3 ± 0.8*** No
  1. ***p < 0.001 with respect to HCC827 cells.